Adenosine receptors and equilibrative nucleoside transporters (AR/ENT)

The adenosine signaling system is a complex physiological network comprising four G protein-coupled receptors (A1, A2A, A2B, and A3) and several nucleoside transporters, most notably the equilibrative nucleoside transporter 1 (ENT1) (Jacobson & Gao, 2006, Nat Rev Drug Discov). This system serves as a critical metabolic sensor and homeostatic regulator; extracellular adenosine levels increase significantly during cellular stress, hypoxia, or inflammation to modulate tissue responses (Fredholm et al., 2001, Pharmacol Rev). Adenosine receptors mediate a wide array of effects, including vasodilation, immunosuppression, and the inhibition of excitatory neurotransmission, while adenosine uptake transporters regulate the duration and intensity of these signals by facilitating the re-uptake of adenosine into cells for metabolic clearance (Baldwin et al., 2004, Pflugers Arch). Pharmacological targeting of this system includes the use of receptor agonists for myocardial stress testing, receptor antagonists for neurodegenerative conditions such as Parkinson's disease, and uptake inhibitors to enhance the protective effects of endogenous adenosine in cardiovascular and ischemic disorders (Chen et al., 2013, Nat Rev Drug Discov). However, the broad expression of these proteins across various tissues often leads to significant therapeutic challenges, including cardiovascular side effects like bradycardia and hypotension (Layland et al., 2004, Cardiovasc Res). Note: The provided target name is considered a composite term referring to multiple distinct protein classes.

Other names

Adenosine signaling systemAdenosine uptake siteNucleoside transporters and adenosine receptorsAdenosinergic systemEquilibrative nucleoside transporter 1 (ENT1)Adenosine A1 receptorAdenosine A2A receptorAdenosine A2B receptorAdenosine A3 receptor

Drugs targeting this system act as adenosine receptor agonists or antagonists, or as inhibitors of adenosine uptake transporters (primarily ENT1) to modulate extracellular adenosine concentrations and downstream signaling pathways.